The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis
| Autor: | Shaoming Song, Shiyi Gong, Tingting Lu, Kehu Yang, Hongwei Tian, Wenwen Yang, Tiankang Guo, Qing-hao Cheng, Kun Lv, Caining Lei |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Disease Cochrane Library Cholangiocarcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Adjuvant therapy Humans Biliary tract cancer Hepatology business.industry Gastroenterology Review manager Regimen Bile Ducts Intrahepatic Biliary Tract Neoplasms Bile Duct Neoplasms Fluorouracil Chemotherapy Adjuvant Meta-analysis Gallbladder Neoplasms business medicine.drug |
| Zdroj: | Clinics and research in hepatology and gastroenterology. 46(2) |
| ISSN: | 2210-741X |
| Popis: | The adjuvant therapy (AT) for biliary tract cancer (BTC) patients after surgery has always been controversial. More therapeutic regimens and high-quality evidence were needed to evaluate AT's survival benefit further. Thus, this study was performed to investigate the efficacy and safety of the 5-fluorouracil (5-FU) regimen in resected BTC patients.PubMed, Cochrane Library, Web of Science, and the Embase were systematically searched from inception to Feb.3, 2021, for eligible studies. The pooled analyses were performed using Review Manager, Stata, and SPSS software.A total of 9 trials involving 1339 participants were included in the meta-analysis. Resected BTC patients could significantly benefit from a 5-FU regimen (HR:0.51, 95%CI, 0.38-0.69, P0.0001), regardless of gallbladder carcinoma (GBC) or cholangiocarcinoma (CCA). Moreover, both adjuvant chemotherapy (HR:0.61, 95%CI, 0.47-0.79, P=0.0003) and chemoradiotherapy (HR:0.35, 95%CI, 0.14-0.83, P=0.02) could significantly improve clinical survival of resected BTC patients than the surgery alone group. In the subgroup analyses, patients with node-positive (P=0.02) or vascular invasion disease (P=0.002) could better benefit from postoperative AT.This study provides the latest evidence to support the 5-FU regimen in resected BTC patients regardless of GBC or CCA. Furthermore, high-risk patients are more likely to benefit from it, such as node-positive or vascular invasion disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect